For young people living with hemophilia B, a lifelong clotting disorder that demands frequent prophylactic infusions, the prospect of a one-time gene correction has long represented a transformative shift in disease management. This Phase 1 trial moves that prospect meaningfully closer for an age group previously excluded from advanced gene therapy research.
The trial enrolled 11 adolescents with hemophilia B and administered an adeno-associated virus (AAV) vector carrying the Padua variant of the Factor IX gene — a naturally occurring gain-of-function mutation that produces a clotting protein with roughly eight to ten times the activity of wild-type Factor IX. All participants tolerated the therapy without serious dose-limiting toxicity, and the cohort demonstrated measurable reductions in annualized bleeding rates following the single-dose intervention. The Padua variant's enhanced potency is central to this approach: it allows therapeutic clotting factor levels to be achieved at lower vector doses, potentially reducing immune-related complications that have historically complicated AAV gene therapy.
This finding carries particular weight because the hemophilia gene therapy field has matured considerably in adults — etranacogene dezaparvovec (Hemgenix) received FDA approval in 2022 for adult hemophilia B — but adolescents have been a conspicuous gap, partly due to concerns about liver growth diluting transgene expression over time. The Phase 1 designation means this trial was primarily powered for safety, not efficacy, so bleeding-rate reductions should be interpreted cautiously with only 11 participants and no control arm. Long-term follow-up will be essential to determine whether Factor IX expression remains durable through the remainder of adolescent development. Nevertheless, for a population that has been systematically underrepresented in pivotal trials, generating preliminary safety and activity data in this age group is an incremental but clinically important step.